Premium
A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection
Author(s) -
Redding Spencer W.,
Farinacci George C.,
Smith Jean A.,
Fothergill Annette W.,
Rinaldi Michael G.
Publication year - 1992
Publication title -
special care in dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.328
H-Index - 41
eISSN - 1754-4505
pISSN - 0275-1879
DOI - 10.1111/j.1754-4505.1992.tb00402.x
Subject(s) - clotrimazole , fluconazole , medicine , thrush , human immunodeficiency virus (hiv) , vulvovaginal candidiasis , dosing , antifungal , dermatology , immunology , cervical cancer , cancer , human papilloma virus
Fluconazole, a newly available triazole, has been evaluated extensively as a treatment for thrush. It has been effective in the treatment of this condition in patients with HIV infection. Clotrimazole troches have been a common treatment for thrush in patients with HIV infection for several years. This study compared the efficacy and safety of fluconazole 100 mg tablets once per day versus clotrimazole 10 mg troches five times per day in the treatment of thrush in patients with HIV infection. Patients were evaluated at baseline, day 7, 14, 28, and 42. The following parameters were evaluated: clinical cure, colonization at the end of treatment, relapse at day 28, and relapse at day 42. Side effects including liver enzyme values were also monitored. Clinical cure was superior with fluconazole tablets than with clotrimazole troches. Also, rates of colonization at the end of therapy and relapse at days 28 and 42 were less with fluconazole tablets than with clotrimazole troches. However, these differences were not statistically significant. Patient compliance with fluconazole was superior to that of clotrimazole. This difference was statistically significant. Both fluconazole tablets and clotrimazole troches are effective in treating thrush in patients with HIV infection. The avoidance of multiple‐per‐day dosing would appear to favor fluconazole.